Patent issues still trouble pharmaceutical companies


The performance of major pharmaceutical companies has been severely hampered over the last year by patents ending and the continuing absence of a president for America’s Food and Drug Administration (FDA).

Large pharmaceutical firms have begun to perform better with the appointment of Mark McClellan as FDA commissioner last November, but firms’ patent problems persist. They do, however, bring with them opportunities for smaller pharmaceutical companies in emerging markets, according to specialist

To continue reading...

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: